



# Biotech Daily

Wednesday March 13, 2019

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH DOWN: PARADIGM UP 12%; GENETIC SIGS DOWN 10%**
- \* **ANTISENSE RAISES \$1.6m TO ACCELERATE ATL1102 FOR DMD**
- \* **REVA FURTHER EXTENDS CAPITAL RAISING SUSPENSION**
- \* **GENERA FURTHER EXTENDS RIGHTS OFFER CLOSING DATE**
- \* **RESAPP EXPECTS \$1.7m R&D TAX INCENTIVE; OFFSHORE FINDING**
- \* **SPILL CALL SHAREHOLDERS TAKE 19% OF FACTOR**
- \* **CEO DR PHILIPPE WOLGEN TAKES 7% OF CLINUVEL**
- \* **CLINUVEL TAKES 9% OF ITSELF**
- \* **E-QUITS ORDERS \$7k ESENSE MARIJUANA TERPENES**
- \* **MGC APPOINTS DR STEPHEN PARKER DIRECTOR**
- \* **RESPIRI APPOINTS GERRY BULLON INVESTOR RELATIONS CONSULTANT**

## MARKET REPORT

The Australian stock market fell 0.22 percent on Wednesday March 13, 2019, with the ASX200 down 13.6 points to 6,161.2 points. Fourteen of the Biotech Daily Top 40 stocks were up, 16 fell, nine traded unchanged and one was untraded.

Yesterday's worst, and apparently a day-traders' delight, Paradigm was the best, up 17 cents or 12.1 percent to \$1.575, with 550,215 shares traded. Prescient climbed seven percent; Cynata and Pro Medicus were up five percent or more; Benitec, Orthocell and Uscom improved more than three percent; Airxpanders and Optiscan rose more than two percent; Actinogen, Kazia, LBT, Pharmaxis and Resmed were up more than one percent; with Clinuvel and Cochlear up by less than one percent.

Genetic Signatures led the falls, down 11.5 cents or 9.6 percent to \$1.085 with 68,772 shares traded. Antisense and Imugene lost five percent or more; Patrys fell 4.55 percent; Avita, Ellex, Medical Developments and Telix were down more than three percent; Polynovo and Universal Biosensors shed more than two percent; Compumedics, CSL, Starpharma and Volpara were down more than one percent; with Mesoblast, Nanosonics and Neuren down by less than one percent.

### ANTISENSE THERAPEUTICS

Antisense says it has raised \$1.6 million in a placement at 3.3 cents a share to accelerate development of ATL1102 for Duchenne muscular dystrophy.

Antisense said the placement was backed by its major institutional investors Australian Ethical Investment and Platinum Asset Management.

The company said the funds would be used to accelerate “development planning for ATL1102 including discussions with regulatory authorities, initially in Europe, on the design and conduct of the next clinical trial of ATL1102 in [Duchenne muscular dystrophy] and on the development path for product registration”.

In January, Antisense said it had recruited five of nine patients in its phase II trial of ATL1102 for Duchenne muscular dystrophy (BD: Aug 29, 2018; Jan 20, 2019).

Today, the company said that regulatory consultants had advised it should seek approval for a phase IIb trial of ATL1102 for Duchenne muscular dystrophy (DMD) to run in parallel with the phase II trial at Melbourne’s Royal Children’s Hospital.

Antisense said it was continuing interactions with Mytomorrows for data and documentation of its ATL1103 early access program for acromegaly.

Antisense managing-director Mark Diamond said the company he welcomed the ongoing support of major shareholders “and look forward to bringing forward regulatory interactions necessary to advance the next stages of development of ATL1102 in DMD”.

“With the current trial due for completion [by the end of this year] we expect to be well positioned to move rapidly into the next phase of development,” Mr Diamond said.

Antisense said that Melbourne’s XEC Partners was the lead managers to the placement.

Antisense fell 0.2 cents or 5.4 percent to 3.5 cents with two million shares traded.

### REVA MEDICAL

Reva says it has requested a further extension to its voluntary suspension until March 21, 2019, pending an announcement of “an accurate update on its capital raising efforts”.

Last week, Reva requested a further extension on its voluntary suspension, following its initial voluntary suspension extension, suspension request and February 18, 2019 capital raising trading halt (BD: Feb 18, Feb 25, Mar 6, 2019).

Reva last traded at 17 cents.

### GENERA BIOSYSTEMS

Genera says it has further extended the closing date for its \$11,446,428 four-for-five entitlement offer at 13 cents a share to March 20, 2019.

In January, Genera said the offer would close on March 1 and last week extended the date to March 15 (BD: Feb 1, 2019).

Genera has been in a suspension at 16 cents, since July 2018 (BD: Jul 2, 4, 2018).

### RESAPP HEALTH

Resapp says it expects to receive \$1,700,000 in the Federal Government Research and Development Tax Incentive program for the year to June 30, 2018.

Resapp said that a finding by the Federal Department of Industry’s Ausindustry made it eligible for overseas research and development expenditure.

The company said the finding covered its US-based paediatric and adult clinical studies for the diagnosis of respiratory disease using cough sounds.

Resapp fell 0.1 cents or 1.1 percent to 8.8 cents.

### FACTOR THERAPEUTICS

The shareholders who called for a Factor board spill say they have increased their holding from 190,617,214 shares (18.28%) to 202,683,121 shares (19.44%).

Last month, the shareholders requested a board spill to replace chair Dr Cherrell Hirst and directors Tim Hughes and John Michailidis with Bruce Lane and David Sanders, with the meeting due to be held on March 29, 2019 (BD: Feb 5, Feb 22, 2019).

Today's substantial shareholder notice said Pura Vida Energy NL acquired 24,107 shares on February 28 for \$96 or 0.4 cents a share, on March 6 it acquired 250,000 shares for \$1,138 or 0.45 cents a share, on March 8 it acquired 361,800 shares for \$1,683 or 0.47 cents a share and on March 11, 2019 it acquired 11,430,000 shares for \$57,779 or 0.51 cents a share.

Factor was untraded at 0.5 cents.

### CLINUVEL PHARMACEUTICALS

Clinuvel chief executive officer Dr Philippe Jacques Wolgen says he has increased his shareholding in Clinuvel from 2,579,722 shares (5.40%) to 3,296,364 shares (6.73%).

Dr Wolgen's substantial shareholder notice said that on March 11, 2019 he exercised 716,642 performance shares at no cost.

Clinuvel was up 25 cents or 0.9 percent to \$28.34 with 132,395 shares traded.

### CLINUVEL PHARMACEUTICALS

Clinuvel and associates says it has increased in itself from 3,721,898 shares (7.80%) to 4,526,214 shares (9.24%).

Clinuvel, Singapore's Vallaurix Pte Ltd and the Melbourne-based ACN 108 768 896 Pty Ltd said that between August 2, 2016 and March 11, 2019 it released 387,531 shares from the Employee Share Scheme Trust and exercised 1,191,847 performance rights.

The company's most recent annual report said that both Vallaurix and ACN 108 768 896 were both wholly owned subsidiaries.

### ESENSE-LAB

Esense-Lab says it has received a \$7,090 order for an additional two litre shipment of its marijuana-infused Lemon Haze terpenes to the UK-based E-Quits Group.

Esense-Lab said \$US5,000 (\$A7,090) was paid in advance for the order.

Esense-Lab was up 0.1 cents or 4.8 percent to 2.2 cents.

### MGC (MEDICAL GRADE CANNABIS) PHARMACEUTICALS

MGC says it has appointed Dr Stephen Parker as a non-executive director, effective from March 13, 2019.

MGC said Dr Parker was currently the non-executive chairman of Sareum Holdings and a non-executive director at Silence Therapeutics.

The company said Dr Parker had investment banking experience at Baring Brothers, SBC Warburg Dillon Read and Apex Partners.

MGC said Dr Parker was a fellow at the Royal Society of Chemistry and the Royal Society of Medicine.

MGC was up 0.1 cents or 2.7 percent to 3.8 cents with 1.2 million shares traded.

## RESPIRI

Respiri says it has appointed Gerry Bullon as its investor relations consultant and “market interface”.

Respiri said Mr Bullon was currently a director at SDI, Longevity Group Australia, Rounded, Recstra and Solo Cover, and chairman of Beames Capital.

The company said that Mr Bullon had 23 years’ experience in investor relations and management consulting, with the majority of his work as principal of the Malvern, Victoria-based Insor.

Respiri was up 0.4 cents or 5.1 percent to 8.2 cents.